Issues
-
Cover Image
Cover Image
Tumor vessels exhibit a wide range of structural and functional defects, which can influence the mechanism by which tumor cells enter the circulation. Due to the challenges associated with observing the dynamics of tumor-vessel interactions deep within tumors in real-time, Silvestri and colleagues developed a 3D tissue-engineered model where primary mammary tumor organoids are cocultured with a functional microvessel. Using fluorescence imaging, it was found that tumor organoids most frequently integrate within the endothelium through gaps in the basement membrane exposing tumor cells to microvessel flow. Other types of interactions observed were vessel constriction and vessel displacement. For details, see article by Silvestri and colleagues on page 4288. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Reviews
Cancer Research Highlights
Genome and Epigenome
Y Chromosome LncRNA Are Involved in Radiation Response of Male Non–Small Cell Lung Cancer Cells
CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
Metabolism and Chemical Biology
Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem–Like Cells and Reduces Metastases through Effects on Lipid Anabolism
Molecular Cell Biology
Tumor Biology and Immunology
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells
Metastasis-Associated Protein 2 Represses NF-κB to Reduce Lung Tumor Growth and Inflammation
Translational Science
Endothelin-1–Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer
High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment
Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts
Convergence and Technologies
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.